CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates

Benjamin K. Watkins, Victor Tkachev, Scott N. Furlan, Daniel J. Hunt, Kayla Betz, Alison Yu, Melanie Brown, Nicolas Poirier, Hengqi Betty Zheng, Agne Taraseviciute, Lucrezia Colonna, Caroline Mary, Gilles Blancho, Jean Paul Soulillou, Angela Panoskaltsis-Mortari, Prachi Sharma, Anapatricia Garcia, Elizabeth Strobert, Kelly Hamby, Aneesah GarrettTaylor Deane, Bruce R. Blazar, Bernard Vanhove, Leslie S. Kean

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Controlling graft-versus-host disease (GVHD) remains a major unmet need in stem cell transplantation, and new, targeted therapies are being actively developed. CD28-CD80/86 costimulation blockade represents a promising strategy, but targeting CD80/CD86 with CTLA4-Ig may be associated with undesired blockade of coinhibitory pathways. In contrast, targeted blockade of CD28 exclusively inhibits T cell costimulation and may more potently prevent GVHD. Here, we investigated FR104, an antagonistic CD28-specific pegylated-Fab', in the nonhuman primate (NHP) GVHD model and completed a multiparameter interrogation comparing it with CTLA4-Ig, with and without sirolimus, including clinical, histopathologic, flow cytometric, and transcriptomic analyses. We document that FR104 monoprophylaxis and combined prophylaxis with FR104/sirolimus led to enhanced control of effector T cell proliferation and activation compared with the use of CTLA4-Ig or CTLA4-Ig/sirolimus. Importantly, FR104/sirolimus did not lead to a beneficial impact on Treg reconstitution or homeostasis, consistent with control of conventional T cell activation and IL-2 production needed to support Tregs. While FR104/sirolimus had a salutary effect on GVHD-free survival, overall survival was not improved, due to death in the absence of GVHD in several FR104/sirolimus recipients in the setting of sepsis and a paralyzed INF-γ response. These results therefore suggest that effectively deploying CD28 in the clinic will require close scrutiny of both the benefits and risks of extensively abrogating conventional T cell activation after transplant.

Original languageEnglish (US)
Pages (from-to)3991-4007
Number of pages17
JournalJournal of Clinical Investigation
Volume128
Issue number9
DOIs
StatePublished - Aug 31 2018

Bibliographical note

Funding Information:
This work was supported by the Yerkes National Primate Research Center (base grant RR00165). The work at the Washington National Primate Research Center was partially supported by grant P51 OD010425 from the NIH Office of Research Infrastructure Programs. This work was also supported by NIH grants HL11879, HL56067, and AI 34495 (to BRB) and by NIH 2U19 AI051731, NIH 1R01 HL095791, and a Burroughs Wellcome Fund Career Award (to LSK). The authors gratefully acknowledge the veterinary and animal husbandry staff at the Yerkes National Primate Research Center and the Washington National Primate Research Center.

Fingerprint Dive into the research topics of 'CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates'. Together they form a unique fingerprint.

Cite this